In This Article:
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on Aug. 2)
-
Akcea Therapeutics Inc (NASDAQ: AKCA)
-
Arbutus Biopharma Corp (NASDAQ: ABUS)
-
AtriCure Inc. (NASDAQ: ATRC)
-
Cytosorbents Corp (NASDAQ: CTSO)
-
Eli Lilly And Co (NYSE: LLY)
-
Glaukos Corp (NYSE: GKOS)
-
Illumina, Inc. (NASDAQ: ILMN)
-
LivaNova PLC (NASDAQ: LIVN)
-
Masimo Corporation (NASDAQ: MASI)
-
Replimune Group Inc (NASDAQ: REPL)
-
Tandem Diabetes Care Inc (NASDAQ: TNDM)
-
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
-
Zoetis Inc (NYSE: ZTS)
Down In The Dumps
(Stocks hitting 52-week lows on Aug. 2)
-
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)
-
Avenue Therapeutics Inc (NASDAQ: ATXI)
-
Bioblast Pharma Ltd (NASDAQ: ORPN)
-
Catabasis Pharmaceuticals Inc (NASDAQ: CATB)
-
CELLECT BIOTECH/S ADR (NASDAQ: APOP)
-
Clovis Oncology Inc (NASDAQ: CLVS)
-
Constellation Pharmaceuticals Inc (NASDAQ: CNST)
-
Cue Biopharma Inc (NASDAQ: CUE)
-
Epizyme Inc (NASDAQ: EPZM)
-
Flex Pharma Inc (NASDAQ: FLKS)
-
Fortress Biotech (NASDAQ: FBIO)
-
IntelliPharmaCeutics Intl Inc (USA) (NASDAQ: IPCI)
-
Midatech Pharma PLC-ADR (NASDAQ: MTP)
-
Radius Health Inc (NASDAQ: RDUS)
-
Vascular Biogenics Ltd (NASDAQ: VBLT)
-
Verrica Pharmaceuticals Inc (NASDAQ: VRCA)
Stocks In Focus Zafgen's Chief Scientific Officer Quits
Zafgen Inc (NASDAQ: ZFGN) said its President and chief scientific officer Thomas Hughes has resigned from the role to take up the CEO position at a privately-held biotech company.
The stock fell 5.69 percent to $9.78 in after-hours trading.
Stocks Reacting to Earnings
TESARO Inc (NASDAQ: TSRO) – plunged 12.45 percent to $31 (reported a loss of $3.04 per share and revenues of $53.89 million, missing the consensus estimates for a loss of $2.65 per share and revenues of $63.34 million)
Acceleron Pharma Inc (NASDAQ: XLRN) – rallied 9.96 percent to $48.02 (reported a Q2 loss of 63 cents, narrower than the 64 cents per share last year)
Adamas Pharmaceuticals Inc (NASDAQ: ADMS) – jumped 13.32 percent to $28.25 (reported a loss of $1.26 compared to the loss of $1.41 per share estimated by analyst; revenues of $7.57 million also trumped the consensus estimate of $4.86 million.
T2 Biosystems Inc (NASDAQ: TTOO) – climbed 9.93 percent to $6.20 (reported Q2 revenues of $3.9 million and an in-line loss of 32 cents per share; The company reiterated its expectations for the full year.)
Pacific Biosciences of California (NASDAQ: PACB) – slumped 9.02 percent to $3.53 (reported below-consensus revenues for Q2 and an in-line loss)
CytoSorbents – rallied 8.14 percent to $13.95 (reported Q2 revenues of $5.8 million, up 61 percent year-over-year and exceeding the consensus estimate; loss was 19 cents per share compared to the year-ago loss of 6 cents per share.)